Navigation Links
Synergy Pharmaceuticals to Present Scientific Posters at the Upcoming Gastroenterology Society Meetings in the U.S. and Europe
Date:7/31/2012

ticals Inc.

Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy's lead proprietary drug candidate plecanatide is a synthetic analog of the human gastrointestinal (GI) hormone uroguanylin, and functions by activating the guanylate cyclase C receptor on epithelial cells of the GI tract. Synergy completed a Phase I study of plecanatide in healthy volunteers and a Phase IIa clinical trial in chronic idiopathic constipation (CIC) patients. In October, 2011, Synergy initiated dosing of patients in a major Phase II/III clinical trial of plecanatide to treat CIC. Plecanatide is also being developed to treat constipation-predominant irritable bowel syndrome (IBS-C), with the first trial in IBS-C patients planned for the second half of 2012. Synergy's second GC-C agonist SP-333 is currently in pre-clinical development to treat inflammatory bowel diseases. More information is available at http://www.synergypharma.com.

About Plecanatide

Plecanatide is a member of a new class of essentially non-systemic drugs, referred to as guanylate cyclase C (GC-C) agonists, that are currently in development to treat CIC and IBS-C. Plecanatide is a synthetic analog of uroguanylin, a natriuretic hormone that regulates ion and fluid transport in the GI tract. Orally-administered plecanatide binds to and activates GC-C receptors expressed on epithelial cells lining the GI mucosa, resulting in activation of the cystic fibrosis transmembrane conductance regulator (CFTR), and leading to augmented flow of chloride and water into the lumen of the gut. Activation of the GC-C receptor pathway is believed to facilitate bowel movement as well as producing other beneficial physiological responses including improvement in abdominal pain and inflammation. In animal models, oral administration of plecanatide promotes intestinal secretion and also ameliorates GI
'/>"/>

SOURCE Synergy Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
4. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
5. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
6. Icahn Issues Statement Regarding Amylin Pharmaceuticals
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
9. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
10. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
11. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Oct. 2, 2014   West Pharmaceutical Services, Inc. ... in innovative solutions for injectable drug administration, announced today ... include a new site in Waterford, Ireland ... for insulin injector cartridges and other high-value packaging components, ... biotech customers. Once operational, this new site could bring ...
(Date:10/1/2014)... DUBLIN, Ohio , Oct. 1, 2014 ... to shareholders is now available. Interested parties can ... and how Cardinal Health is supporting the ... at http://cardinalhealth.com/annualreport . Photo- ... addition to summary financials and the chief ...
(Date:10/1/2014)... 1, 2014  ResMed (NYSE: RMD ), a ... company to design complete sleep apnea solutions specifically for women, ... importance of a good night,s sleep. The ... that feeling tired is just part of living a busy ... a critical pillar of health, essential to not only living ...
Breaking Medicine Technology:West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 2West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 3West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 4West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 5Cardinal Health 2014 Digital Report to Shareholders Now Available 2ResMed Launches Initiative to Help Women Get Better Sleep 2ResMed Launches Initiative to Help Women Get Better Sleep 3
(Date:10/2/2014)... Originally considered alternative food only ... increasingly popular with consumers. This has fuelled demand ... industry in Australia. According to IBISWorld industry ... has surged over the past five years, contributing ... level.” Over the five years through 2014-15, industry ...
(Date:10/2/2014)... Maureen Salamon HealthDay ... -- Middle-aged women with a neurotic personality style and ... Alzheimer,s disease, new research suggests. Tracking 800 women ... who were most anxious, jealous and moody -- which ... had double the risk of developing Alzheimer,s compared to ...
(Date:10/2/2014)... (HealthDay News) -- Children with autism are more sedentary ... of being more active, a small study suggests. ... children, some with autism and some without. Children with ... physical activity and 70 more minutes each day sitting ... autism scored lower on strength, but had similar body-mass ...
(Date:10/2/2014)... Amy Norton HealthDay Reporter WEDNESDAY, ... smelling the roses -- literally -- may face an increased risk ... In a study of over 3,000 older Americans, researchers found those ... peppermint were more than three times as likely to die in ... smell. In fact, anosmia -- the inability to distinguish odors ...
(Date:10/2/2014)... medical discovery by scientists at The University of Nottingham ... type of painkiller. , A drug resulting from the ... , would offer new hope to sufferers of chronic ... few effective painkillers are currently available. , The work, ... of Life Sciences, in collaboration with David Bates, Professor ...
Breaking Medicine News(10 mins):Health News:Organic Livestock and Poultry Farming in Australia Industry Market Research Report Now Available from IBISWorld 2Health News:Organic Livestock and Poultry Farming in Australia Industry Market Research Report Now Available from IBISWorld 3Health News:Organic Livestock and Poultry Farming in Australia Industry Market Research Report Now Available from IBISWorld 4Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 3Health News:Kids With Autism Tend to Be Less Active, Study Says 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3Health News:Medical discovery first step on path to new painkillers 2
... PhD, president of The J. David Gladstone Institutes, ... The award recognizes his leadership as Gladstone,s founding ... one of the world,s foremost independent research institutions, ... impact on disease prevention. Mahley will be ...
... ... regarding 2010 Shanghai, China Expo -- attracting attention from all walks of life. , ... Beijing (PRWEB) February 10, 2010 -- ... biggest World Expo in the history of world expositions. , , ,This special tour has ...
... women don,t know it is leading killer, survey finds , ... almost half of all American women still don,t know that ... new research finds. , Even more concerning, only slightly more ... they were having heart attack symptoms, according to the latest ...
... with Inflammatory Bowel Disease (IBD) are known to be at high ... of their disease but now new research by scientists at The ... to hospital during flare-ups are also at risk. The two ... affect about one in every 250 people in the UK. The ...
... ... to learn how to differentiate from competition and manage risk. , ... Lafayette, CO (PRWEB) February 10, 2010 -- Auto dealers will be able ... lead-generation, HR best practices and OSHA regulations at the Orlando NADA Convention and Expo 2010., , ...
... Poll Finds Voters Prefer Tobacco Tax to Other Tax Increases, Budget Cuts ... Utah ,s cigarette tax by $1 per pack would bring ... the state,s budget shortfall, while also reducing smoking and saving lives, according ... organizations.  In Utah, health advocates are calling on state leaders to increase ...
Cached Medicine News:Health News:Gladstone's Robert Mahley to receive Research!America advocacy award 2Health News:Jion Beijing Great Wall International Travel Agency Immediate Exposure to China Expo 2010 2Health News:Women's Heart Disease Awareness Still Lacking 2Health News:Women's Heart Disease Awareness Still Lacking 3Health News:Bowel disease link to blood clots 2Health News:Bowel disease link to blood clots 3Health News:KPA and TK Carsites offer HR, OSHA and Internet Marketing Workshops at the NADA Convention and Expo 2010 2Health News:New Report: $1 Cigarette Tax Increase Would Raise $43.3 Million for Utah and Cut Youth Smoking 2Health News:New Report: $1 Cigarette Tax Increase Would Raise $43.3 Million for Utah and Cut Youth Smoking 3
It provides excellent illumination from an inexpensive platform and is mounted on the comfortable UltraLite headband....
It is a fiberoptic based intracranial monitoring systems for continuous monitoring of pressure....
... The Polaris system delivers the most ... effective and easy to use, this ... of precision measurement with unprecedented tracking ... active and passive tools, the Polaris ...
Penfield Dissector #2...
Medicine Products: